Tabakkonsum: Was ist das und wie kann der Schaden gemindert werden?

Zusammenfassung

Die Kulturgeschichte des Tabaks im Westen beginnt mit seiner Entdeckung durch Columbus 1492. Die heutige Debatte um Schaden und Schadenminderung krankt an ungenügenden Definitionen, indem Substanz und Konsumform ungenügend auseinander gehalten und unzulässige Analogieschlüsse gezogen werden. Bei der heute gebräuchlichsten Form des Tabakkonsums, dem Zigarettenrauchen, geht die Gefährlichkeit nicht direkt vom Tabak aus, sondern von seiner Konsumform und die mit dem Tabakkonsum verbundene Nikotinabhängigkeit ist nicht die Hauptschädigung. Davon abgeleitet können verschiedene Schadenminderungsstrategien formuliert werden, beginnend mit weniger rauchen über Modifizierung der Tabakinhalts- und Verbrennungsstoffe bis hin zum Ersatz der Konsumform durch orale Einnahme.

Abstract

The cultural history of tobacco in the Western world starts with its discovery by Columbus in 1492. The actual debate on harm and harm re duction lacks sufficient definitions in the sense that substance and forms of use are mixed up and not allowed analogy conclusions were drawn. The harm of the actual predominant form of tobacco use, the smoking of cigarettes, doesn’t stem directly from the tobacco, but from the form of use and the nicotine addiction related to tobacco use isn’t the main harm. From this several strategies of harm reduction can be formulated, starting with smoking less to modification of tobacco content and combustion products, up to replacement of the form of use by oral forms of use.

Tabak - Nikotin - Zigaretten - Risiken - Schadenminderung - Konsumformen

tobacco - nicotine - cigarettes - risks - harm reduction - forms of use

Literatur

• 1 Conte Corti EC. Geschichte des Rauchens.. „Die trockene Trunkenheit”. Insel Verlag; 1986
• 2 Wilbert J. Le tabac et l’extase chamanique chez les indiens Warao du Venezuela.  L’Esprit frappeur. 2000; 
• 3 Mündl K. Tabak: ein Kraut verändert die Welt.  Styria. 2001; 
• 4 Wilbert J. Tobacco and shamanism in South America.  Yale University Press. 1987; 
• 5 Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics.  Annu Rev Pharmacol Toxicol. 2009;  49 57-71
• 6 Strasser AA, Malaiyandi V, Hoffmann E. et al . An association of CYP2A6 genotype and smoking topography.  Nicotine Tob Res. 2007;  9 511-518
• 7 Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.  Clin Pharmacol Ther. 2008;  83 531-541
• 8 Sun W, Hansen A, Zhang L. et al . Neonatal nicotine exposure impairs development of auditory temporal processing.  Hear Res. 2008;  245 58-64
• 9 Chen WJ, King KA, Lee RE. et al . Effects of nicotine exposure during prenatal or perinatal period on cell numbers in adult rat hippocampus and cerebellum: a stereology study.  Life Sci. 2006;  79 2221-2227
• 10 Vaglenova J, Birru S, Pandiella NM. et al . An assessment of the long-term developmental and behavioral teratogenicity of prenatal nicotine exposure.  Behav Brain Res. 2004;  150 159-170
• 11 Winzer-Serhan UH. Long-term consequences of maternal smoking and developmental chronic nicotine exposure.  Front Biosci. 2008;  13 636-649
• 12 Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease.  Mayo Clin Proc. 2005;  80 652-656
• 13 Talhout R, Opperhuizen A, van Amsterdam JG. Role of acetaldehyde in tobacco smoke addiction.  Eur Neuropsychopharmacol. 2007;  17 627-636
• 14 Talhout R, Opperhuizen A, van Amsterdam JG. Sugars as tobacco ingredient: Effects on mainstream smoke composition.  Food Chem Toxicol. 2006;  44 1789-1798
• 15 Stratton K, Shetty P, Wallace R. et al . Clearing the smoke: the science base for tobacco harm reduction – executive summary.  Tob Control. 2001;  10 189-195
• 16 Pisinger C, Godtfredsen NS. Is there a health benefit of reduced tobacco consumption? A systematic review.  Nicotine Tob Res. 2007;  9 631-646
• 17 Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk.  JAMA. 2005;  294 1505-1510
• 18 Zhu SH, Pulvers K, Zhuang Y. et al . Most Latino smokers in California are low-frequency smokers.  Addiction. 2007;  102 (S 02) 104-111
• 19 Drinkmann A. Kontrolliertes Rauchen: Standortbestimmung und Perspektiven.  Suchttherapie. 2002;  3 81-86
• 20 Godtfredsen NS, Prescott E, Vestbo J. et al . Smoking reduction and biomarkers in two longitudinal studies.  Addiction. 2006;  101 1516-1522
• 21 Batra A, Klingler K, Landfeldt B. et al . Smoking reduction treatment with 4 mg nicotine gum: a double-blind, randomized, placebo-controlled study.  Clin Pharmacol Ther. 2005;  78 689-696
• 22 Hatsukami DK, Le CT, Zhang Y. et al . Toxicant exposure in cigarette reducers versus light smokers.  Cancer Epidemiol Biomarkers Prev. 2006;  15 2355-2358
• 23 Strasser AA, Lerman C, Sanborn PM. et al . New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure.  Drug Alcohol Depend. 2007;  86 294-300
• 24 Breland AB, Kleykamp BA, Eissenberg T. Clinical laboratory evaluation of potential reduced exposure products for smokers.  Nicotine Tob Res. 2006;  8 727-738
• 25 Colilla SA. An epidemiologic review of smokeless tobacco health effects and harm reduction potential.. Regul Toxicol Pharmacol. Jahrgang: Seiten??; 2009
• 26 Foulds J, Ramstrom L, Burke M. et al . Effect of smokeless tobacco (snus) on smoking and public health in Sweden.  Tob Control. 2003;  12 349-359
• 27 Rosenquist K. Risk factors in oral and oropharyngeal squamous cell carcinoma: a population-based case-control study in southern Sweden.  Swed Dent J Suppl. 2005;  179 1-66
• 28 Melikian AA, Hoffmann D. Smokeless tobacco: a gateway to smoking or a way away from smoking.  Biomarkers. 2009;  14 (S 01) 85-89
• 29 Tomar SL, Fox BJ, Severson HH. Is smokeless tobacco use an appropriate public health strategy for reducing societal harm from cigarette smoking?.  Int J Environ Res Public Health. 2009;  6 10-24
• 30 Gilpin EA, Pierce JP. The California Tobacco Control Program and potential harm reduction through reduced cigarette consumption in continuing smokers.  Nicotine Tob Res. 2002;  4 (S 02) S157-S166
• 31 Zhu SH, Wang JB, Hartman A. et al . Quitting cigarettes completely or switching to smokeless tobacco: do US data replicate the Swedish results?.  Tob Control. 2009;  18 82-87
• 32 Foulds J, Furberg H. Is low-nicotine Marlboro snus really snus?.  Harm Reduct J. 2008;  5 9
• 33 Ramstrom LM, Foulds J. Role of snus in initiation and cessation of tobacco smoking in Sweden.  Tob Control. 2006;  15 210-214
• 34 Martinet Y, Bohadana A, Fagerstrom K. Would alternate tobacco products use be better than smoking?.  Lung Cancer. 2006;  53 1-4

Korrespondenzadresse